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Abstract
Background: Different parameters have been determined for prediction of treatment outcome in hepatitis c virus genotype
1 infected patients undergoing pegylated interferon, ribavirin combination therapy. Results on the importance of vitamin D
levels are conflicting. In the present study, a comprehensive analysis of vitamin D levels before and during therapy together
with single nucleotide polymorphisms involved in vitamin D metabolism in the context of other known treatment
predictors has been performed.
Methods: In a well characterized prospective cohort of 398 genotype 1 infected patients treated with pegylated interferon-
a and ribavirin for 24–72 weeks (INDIV-2 study) 25-OH-vitamin D levels and different single nucleotide polymorphisms were
analyzed together with known biochemical parameters for a correlation with virologic treatment outcome.
Results: Fluctuations of more than 5 (10) ng/ml in 25-OH-vitamin D-levels have been observed in 66 (39) % of patients
during the course of antiviral therapy and neither pretreatment nor under treatment 25-OH-vitamin D-levels were
associated with treatment outcome. The DHCR7-TT-polymorphism within the 7-dehydrocholesterol-reductase showed a
significant association (P= 0.031) to sustained viral response in univariate analysis. Among numerous further parameters
analyzed we found that age (OR= 1.028, CI = 1.002–1.056, P= 0.035), cholesterol (OR= 0.983, CI = 0.975–0.991, P,0.001),
ferritin (OR= 1.002, CI = 1.000–1.004, P= 0.033), gGT (OR= 1.467, CI = 1.073–2.006, P= 0.016) and IL28B-genotype (OR= 2.442,
CI = 1.271–4.695, P= 0.007) constituted the strongest predictors of treatment response.
Conclusions: While 25-OH-vitamin D-levels levels show considerable variations during the long-lasting course of antiviral
therapy they do not show any significant association to treatment outcome in genotype 1 infected patients.
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Introduction
Almost 3% of the world population is chronically infected with
hepatitis c virus (HCV) and thus potentially confronted with life-
threatening complications such as liver cirrhosis and liver cancer
[1]. During permanent attempts to improve therapeutic strategies,
beside the recent approval of two novel direct acting antiviral
compounds [2], several predictors of treatment response have
been identified [3] with recent studies including gamma-glutamyl-
transferase (gGT) [4], cholesterol [5], early viral kinetics [6],
interferon-c-inducible-protein-10 (IP10) [7], ferritin [8] and the
interleukin-28B (IL28B) polymorphism [9] as further important
predictors of sustained viral response (SVR) as well. However, the
pursuit of further surrogate factors able to optimize therapeutic
regimes remains challenging.
Beside the above mentioned parameters many studies suggested
vitamin D (VitD) as an additional predictor of SVR, whereas low
pretreatment levels of 25-OH-Vitamin D3 (25(OH)D3) (,20 ng/
ml) associated significantly with low responsiveness to antiviral
therapy[10–14]. However, recent findings also indicate that the
pretreatment concentration of VitD is not always capable of
predicting treatment outcome in chronic HCV infection [15] as
well as in HCV/HIV-coinfected patients [16,17]. Moreover,
serum concentrations of 25(OH)D3 are getting affected by various
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factors such as nutrition, comorbidities and seasonal sunlight
exposure [18] and since an additional hydroxylation step is
needed, 25(OH)D3-levels just offer an indirect association to the
active form of VitD, 1,25(OH)2D3. The latter has a half-life of only
4 hours and is detectable in much lower serum concentrations
than 25(OH)D3. 1,25(OH)2D3 is additionally strongly affected by
the serum levels of calcium, phosphate and parathyroid hormone
with clinical guidelines still recommending the routine assessment
of 25(OH)D3 as the appropriate parameter in order to monitor the
VitD status of patients [19]. In this context genetic polymorphisms
within key enzymes regulating the pathophysiology of VitD have
been shown to affect substantially VitD signaling in clinical
diseases [20,21]. In chronic HCV infection genetic polymorphisms
within VitD binding proteins [12], the CYP27B1-hydroxylase [22]
and the VitD-receptor [23] have been shown to correlate
significantly with the outcome of antiviral therapy.
Purpose of the present study is therefore to evaluate the
predictive potential of serum VitD levels both prior to as well as
during antiviral therapy in a large (n = 398), well characterized
cohort of genotype 1 HCV infected patients treated prospectively
with pegylated interferon-a (PEG-IFNa) and ribavirin (RBV) for
24–72 weeks (INDIV-2 study) [24]. Since liver histology and
genetic data were available in the majority of patients, we
additionally evaluated genetic polymorphisms within major
enzymes regulating 25(OH)D3- and 1,25(OH)2D3-concentrations,
CYP2R1, CYP27B1, DHCR7, CYP24A1 and within VitD binding
proteins (DBP). Findings concerning the prediction of treatment
outcome were further analyzed in association with several
prognostic parameters being available prior to initiation, during
and after completion of antiviral therapy in our patient cohort.
Patients and Methods
Patients
In the current study we evaluated retrospectively the predictive
potential of various parameters regarding treatment outcome in a
cohort of 398 patients treated prospectively with PEG-IFNa/RBV
as previously described [24]. Histologic results of liver biopsies
were available for 378 out of 398 patients (95% of all patients).
Genotyping for IL28B, CYP27B1, CYP2R1, CYP24A1, DHCR7 and
DBP was determined in all patients being agreeable to genetic
analysis (375 out of 398, 94% of all patients). Demographic
characteristics and clinical parameters assessed prior to, during
and after antiviral therapy were extracted from the INDIV-2
clinical database [24]. Uni- and multivariate analysis were
performed to evaluate possible associations between SVR and
various variables such as age, sex, body mass index (BMI), liver
fibrosis, IL28B-, CYP27B1-, CYP2R1-, CYP24A1-, DHCR7-, DBP-
genotype, VitD levels at baseline and week 24 of antiviral therapy,
IP10-levels at baseline and week 1 and 4 of antiviral therapy,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), gamma-glutamyl-transferase (gGT), alkaline phosphatase
(AP), bilirubin, cholesterol, triglycerides, thyroid stimulating
hormone (TSH), ferritin and homeostatic model assessment of
insulin resistance (HOMA) by means of a logistic regression model
with SVR being the dependent variable as explained further in the
statistical analysis. Clinical biochemistry values such as glucose,
cholesterol and triglycerides were transformed to uniform mea-
surement units to render data comparable to each other. The
design of the study has been described previously [24]. The study
was performed in accordance with the Declaration of Helsinki and
was approved by the local ethics committee (Ethik-Kommission,
University Hospital Frankfurt). All patients had signed a written
informed consent prior to study inclusion.
Quantification of IP10- and VitD-levels
The commercially available human CXCL10/IP-10 Quanti-
kine ELISA Kit, provided by R&D systems, was used for
quantification of IP10 levels. 75 ml patient-serum was used for
every measurement performed according to the manufacturer’s
instructions. 25(OH)D3 concentrations were quantified by the
I125–radioimmunoassay IA Kit, provided by DiaSorin. In this case
50 ml patient-serum was used for every measurement performed
according to the manufacturer’s instructions. Quantification of
both IP10- and 25(OH)D3- levels and genotyping of VitD genetic
polymorphisms was performed retrospectively whereas all samples
were stored at 280uC until assayed.
Genotyping of Single Nucleotide Polymorphisms
We evaluated the predictive potential of IL28B (rs12979860)
variants, CYP27B1 (rs10877012) promoter-, the CYP2R1
(rs10741657) hydroxylase-, the CYP24A1 (rs6013897) hydroxy-
lase-, the DHCR7 (rs12785878 and rs7944926) reductase- as well
as DBP (rs2282679, rs4588 and rs7041) binding protein-polymor-
phisms on treatment outcome. Genotyping of IL28B was
performed as described before [25]. For the determination of
CYP2R1- (rs10741657), CYP27B1-(rs10877012) and DBP (rs4588
and rs7041) polymorphisms DNA was amplified with the
respective primers, with PCR conditions and enzymes as
previously described [26,27]. The polymorphisms within the
DHCR7 reductase-gene (rs12785878/C_32063037_10 and
rs7944926/C_12043682_10), DBP (rs2282679/C_26407519_10)
and CYP24A1- (rs6013897/C_22958084_10) were analyzed in the
laboratory of molecular endocrinology of our department using
Taqman assays in an ABI 7300 PCR System under the conditions
recommended by the manufacturer (Applied Biosystems, Darm-
stadt, Germany) as previously described [26].
Statistical Analysis
Statistical analysis of the data was performed using the BIAS
software package (BiAS for Windows, program version 9 ,
Epsilon, 1989–2012). Continuous variables are presented as mean
values (range) and categorical variables are presented as frequen-
cies (%). Assessment of significant associations between continuous
variables as for instance age, BMI, ALT, AST, gGT, AP, bilirubin,
ferritin, HOMA-index, cholesterol, triglycerides, 25(OH)D3, IP10,
TSH and treatment endpoints (SVR) were carried out via the
Wilcoxon-Mann-Whitney-U-test. Dichotomic variables (e.g. sin-
gle-nucleotide-polymorphisms (SNP’s), fibrosis stage, sex, treat-
ment outcome) were assessed by means of contingency tables,
Mantel-Haenszel-test, as appropriate. After univariate analysis
stepwise logistic regression analysis with a backward selection,
using a P value $0.1 for removal from the model, was performed
to identify independent predictors of SVR. Parameters with
significant associations derived from univariate analysis as well as
sex and age were included into the model. Only patients with
complete data for the predicting covariates were included in




The INDIV-2-study cohort included 398 patients with geno-
type-1 chronic HCV infection treated prospectively with PEG-
IFNa/RBV for different treatment durations. Length of treatment
was individualized for every patient according to baseline viral
load and virologic response rates assessed at different time points
upon initiation of antiviral therapy [24]. Biochemical, virologic,
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histologic and demographic characteristics of the patient cohort
are shown in Table 1.
Baseline and under Therapy Vitamin D Levels Unable to
Predict Treatment Outcome
25(OH)D3- levels have been assessed retrospectively prior to
and during antiviral treatment (on therapy week 24, TW24) in
respectively available blood samples. Mean concentrations at both
time points (18,7 ng/ml and 19,5 ng/ml respectively) reveal a
VitD-deficiency among the patient cohort (Table 1), since levels .
30 ng/ml are proposed as normal VitD concentrations in serum
by clinical guideline recommendations [19]. In our analysis we
further observed variations within VitD-levels during the course of
antiviral therapy, whereas environmental factors like the month of
blood sample collection, affected significantly the levels of the
measured 25(OH)D3-concentrations (Figure 1A). Furthermore,
during the long-lasting course of antiviral therapy 66% of patients
exhibited a VitD-level-difference (DVitD) of $5 ng/ml between
VitD-levels assessed at baseline and at TW24 (Figure 1B).
Impressively in 39% of patients even more pronounced variations
of VitD-levels (.10 ng/ml) have been observed (Figure 1B).
However, no significant association between VitD-concentrations
and SVR-rates was observed in uni- and multivariate analysis for
both time points (Table 2). Furthermore, no significant association
of baseline VitD levels to HCV-RNA kinetics was observed.
Patients with rapid viral response (RVR) showed a positive,
however statistically non-significant correlation to higher baseline
VitD values as compared to patients with no RVR (21,04 versus
18,84 ng/ml respectively, P=0.554). Also DVitD-values were
despite the observed variability unable to predict SVR rates
Table 1. Patient demographic, biochemical and genetic characteristics.
Patient demographic biochemical and genetic data Mean (Range)
Age 43,1 (18–70)
Sex (female/male) *n, [%] 182* [45,7%]/216* [54,3%]
BMI (kg/m2) 25,5 (16,6–45,5)
ALT_fact (times upper limit of normal, IU/l) 1,9 (0,3–12,9)
AST_fact (times upper limit of normal, IU/l) 1,34 (0,43–7,96)
GGT_fact (times upper limit of normal, IU/l) 1,3 (0,2–16,1)
HOMA-index 3,19 (0,1–22,6)
Ferritin (mg/l) 174 (3,7–1846)
Triglyceride (mg/dl) 104,4 (16–490)
AP (IU/l) 70,4 (32–204)
TSH (mIU/ml) 1,52 (0,01–12)
Fasting glucose (mg/dl) 94 (60–201)
Cholesterol (mg/dl) 174 (61–320)
Vitamin D baseline (ng/ml) 18,7 (3–84,3)
Vitamin D TW 24 (ng/ml) 19,5 (3,2–61,9)
IP10 baseline (pg/ml) 254 (41,2–2000)
HCV-RNA (log IU/ml) 5,6 (2,8–6,9)
HCV-subtype (1a/1b/1c) 109 (33,3%)/210 (64,2%)/8 (2,4%)
IL28B-rs12979860 (CC/non_CC) 117 (31,8%)/250 (68,1%)
CYP27B1-rs10877012 (AA/non_AA) 39 (10,6%)/327 (89,3%)
CYP2R1- rs10741657 (AA/non_AA) 51 (13,9%)/315 (86,1%)
DHCR7-rs12785878 (TT/non_TT) 198 (52,8%)/177 (47,2%)
CYP24A1-rs6013897 (TT/non_TT) 232 (61,8%)/143 (38,1%)
DHCR7-rs7944926 (GG/non_GG) 204 (54,2%)/172 (45,7%)
DBP-rs2282679 (TT/non_TT) 196 (52,2%)/179 (47,7%)
DBP-rs4588 (CC/non_CC) 188 (50,1%)/187 (49,9%)
DBP-rs7041 (GG/non_GG) 115 (30,6%)/260 (69,3%)
Fibrosis stage (0–2/3–4) *n, [%] 321 [84,9%]/57 [15,1%]
A VitD deficiency (,20 ng/ml) was observed in 251 (64,1%) out of 391patients. A liver fibrosis stage of 0–2 was observed in 321 (84,9%) out of 378 patients, while 57
(15%) out of 378 patients showed a liver fibrosis stage of 3–4.
Abbreviations: BMI: body-mass-index, ALT: alanine aminotransferase, AST: aspartate aminotransferase, gGT: gamma-glutamyl-transferase, HOMA: homeostatic model
assessment of insulin resistance, AP: alkaline phosphatase, TSH: thyroid stimulating hormone, IP10: interferon-c-inducible-protein-10, HCV: hepatitis C virus.
Missing data: Cholesterol levels were missing in 14 patients, Baseline Vitamin D levels were missing in 7 patients, Baseline IP10 levels were missing in 7 patients, Baseline
viral load values were missing in 16 patients, Liver biopsy status was missing in 20 patients. HOMA-index values were missing in 74 patients, Triglyceride levels were
missing in 15 patients, AP levels were missing in 4 patients, Ferritin levels were missing in 10 patients, Vitamin D levels on week 24 were missing in 69 patients, IP10
levels on week 1 were missing in 23 patients, IP10 levels on week 4 were missing in 42 patients, TSH values were missing in 6 patients, Genotype of the IL28B-gene was
missing in 31 patients, Genotype of the CYP27B1-gene was missing in 32 patients, Genotype of the CYP2R1-gene was missing in 32 patients, Genotype of the DHCR7-
genes was missing in 24 patients, Genotype of the CYP24A1-gene was missing in 24 patients, Genotype of the DBP-genes was missing in 24 patients.
doi:10.1371/journal.pone.0087974.t001
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(P=0.058). When solely patients with severe VitD-deficiency (,
10 ng/ml) or normal serum VitD-values ($30 ng/ml) at baseline
were included in the analysis, SVR-rates of 61% versus 48% were
observed, respectively. Patients with a severe VitD-deficiency both
at baseline and TW24 achieved a SVR in 74% while patients with
normal VitD-concentrations both at baseline and TW24 achieved
a SVR in 76% of cases with no significant differences observed in
both groups. When serum probes were taken during the summer
months (May to August) mean VitD levels were slightly higher as
compared to serum probes taken during the winter months
(November to February) (18,9 versus 16,4 ng/ml respectively).
However, no significant associations of VitD levels to SVR rates
were observed both when only patients with VitD levels evaluated
during the summer (16,2 versus 21,2 for SVR versus nonSVR
respectively, P=0.056) as well as when only patients evaluated
during the winter months were considered in the analysis (16,3
versus 17,3 for SVR versus nonSVR respectively, P=0.8).
SNP’s within Vitamin D Regulating Enzymes
Various SNP’s within several enzymes of VitD metabolism
(CYP2R1, CYP27B1, CYP24A1 and DHCR7) have been by previous
studies identified to have substantial impact on the serum
concentrations of 25(OH)D3 [28]. In our analysis no significant
correlation of most SNP’s to SVR rates was identified (Table 2). In
particular, we evaluated the predictive potential of the already
proposed CYP27B1-SNP (rs10877012) in the promoter of the
VitD-1a-Hydroxylase [22] on treatment outcome in our patient
cohort. Regarding the induction of SVR we observed solely a non-
significant trend of the AA-allele in univariate analysis (P=0.067)
(Table 2). The only significant association to SVR rates was
observed for the DHCR7-SNP (rs12785878) in univariate analysis
(P=0.031), whereas adjustment for further predictive factors
eliminated this parameter from the regression model in multivar-
iate analysis (Table 2). Further SNP’s within VitD binding proteins
(DBP-rs4588 and -rs7041) previously highlighted to associate
significantly with the outcome of antiviral therapy [12] didn’t show
any significant correlation to SVR rates in our patient cohort
(Table 2). Furthermore, solely DHCR7-SNP’s (rs12785878 and
rs7944926) showed a significant association to baseline VitD levels
(P=0.014 and P=0.002 respectively) (Table 3) whereas DVitD-
values during antiviral therapy didn’t show any significant
association to all SNP’s analyzed (Table 3).
Parameters Independently Predicting SVR-rates
Several parameters were significantly associated with the
induction of SVR in univariate analysis as shown in Table 2.
However, only a part of these parameters constituted independent
predictors of treatment response, identified by a multivariate
logistic regression model, in our analysis. The induction of SVR
was independently predicted by age (OR=1.029, CI = 1.002–
1.057, P=0.032), cholesterol (OR=0.983, CI = 0.975–0.991, P,
0.001), ferritin (OR=1.002, CI = 1.000–1.004, P=0.032), gGT
(OR=1.467, CI = 1.068–1.995, P=0.017) and IL28B-genotype
(OR=2.476, CI = 1.289–4.757, P=0.006). Low baseline gGT-
levels and high baseline cholesterol concentrations feature the two
clinical parameters with the highest independent predictive
potential beside demographic and genetic patient characteristics
(Figure 2). Low IP10-levels at baseline, therapy week 1 and
therapy week 4 were significantly associated with the induction of
SVR (P=0.009, P=0.015, P=0.010 respectively) in univariate
analysis, whereas no significant associations were observed in
multivariate analysis (Table 2). 358 out of 391 patients had an
IP10 baseline level of ,600pg/ml which was suggested by
previous studies to be favorable for the achievement of SVR
upon PEG-IFN/RBV combination therapy [29]. The observed
variations of IP10 levels during the course of antiviral therapy
(Figure 3) were unable to predict treatment outcome (data not
shown). Since many studies suggested a significant improvement in
the prediction of SVR by combination of IP10-levels and IL28B-
genotype [29,30] we also analyzed the predictive ability of IP10-
levels separately in patients with the favorable IL28B-CC-genotype
and in non-CC-patients. Accordingly, in IL28B-CC-patients
achieving an SVR, IP10-levels were lower (243 pg/ml) than in
patients without SVR (265 pg/ml) but not significantly associated
with SVR (P=0.7). However, in IL28B-nonCC-patients a
significant association between IP10-levels and SVR was observed
(222 and 299 pg/ml, in SVR and nonSVR-patients respectively,
P= 0.002).
Discussion
In the present study we examined thoroughly the predictive
potential of baseline and under therapy VitD-levels as well as of
their fluctuations during antiviral therapy on treatment outcome in
a well characterized cohort of 398 genotype 1 patients treated
prospectively with PEG-IFN/RBV for variable time periods.
Furthermore, we included a comprehensive evaluation of genetic
polymorphisms within VitD regulating enzymes that have been
Figure 1. VitD concentrations vary dependent on the month of
sample obtainment (1A), whereas fluctuations between base-
line-VitD and TW24-VitD-values (DVitd) are observed as well
(1B).
doi:10.1371/journal.pone.0087974.g001
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previously shown to affect VitD concentrations or to associate with
outcome of antiviral therapy. Among all parameters screened we
identified younger age, elevated baseline cholesterol levels, low
baseline gGT and ferritin levels as well as the IL28B-CC-genotype
as independent predictors of reaching a SVR whereas VitD levels,
their under-therapy-fluctuations and most of the SNP’s within
VitD regulating enzymes were not able to predict treatment
outcome.
Recent findings from various studies investigating the role of
VitD in chronic HCV infection offer conflicting evidence
regarding the predictive potential of pretreatment VitD concen-
trations upon antiviral therapy regimes. On the one hand low
pretreatment VitD-concentrations are suggested to correlate with
poor responsiveness to antiviral therapy [10–14] and on the other
hand in 269 patients infected with various HCV genotypes [15]
and in 317 patients infected with genotype 1 [22], all treated
prospectively with PEG-IFN/RBV, VitD levels seem unable to
predict treatment response. Furthermore, baseline VitD concen-
trations failed to prognosticate outcome of antiviral therapy in
HCV/HIV-coinfected patients as well [16,17], thus further
subsidizing the already observed controversy. However, assess-
ment of VitD concentrations solely prior to treatment initiation as
well as incomplete consideration of environmental and genetic
factors affecting VitD levels constitute possible sources of bias in
hitherto existing analyses. In the present study we intended to
overcome some of these limitations by measuring VitD concen-
trations also at TW24 and by considering the seasonal variability
of VitD levels and the effect of SNP’s within major regulatory
Table 2. Uni- and multivariate analysis of predictors of SVR to antiviral therapy.
Patient characteristics Univariate analysis Multivariate analysis
SVR Mean (Range) non-SVR Mean (Range) p-value OR (95% CI) p-value
Age (years) 42 (18–68) 46 (19–70) ,0.001 1.029 (1.002–1.057) 0.032
Sex (female/male) *n, [%] 106* [26,6%]/111*[27,8%] 76* [19,0%]/104* [26,1%] 0.1
BMI (kg/m2) 24.7 (17.3–45.5) 24.7 (16.6–42.9) 0.5
ALT_fact (times upper limit
of normal, IU/l)
1.64 (0.31–9.8) 1.56 (0.36–12.8) 0.4
AST_fact (times upper limit
of normal, IU/l)
1.09 (0.43–7.96) 1.1 (0.48–7.89) 0.3
GGT_fact (times upper limit
of normal, IU/l)
0.71 (0.15–7.31) 1.28 (0.25–16.08) ,0.001 1.46 (1.068–1.995) 0.017
HOMA-index 1.75 (0.3–20) 2.55 (0.1–22.6) ,0.001 0.949 (0.87–1.036) 0.2
Cholesterol (mg/dl) 182 (101–320) 166.2 (61–289) ,0.001 0.983 (0.975–0.991) ,0.001
Triglyceride (mg/dl) 89 (25–422) 93 (16–490) 0.7
AP (IU/l) 65 (32–181) 71.5 (32–204) ,0.001 1.011 (0.997–1.026) 0.09
Ferritin (mg/l) 101 (3.7–780) 153 (6–1846) ,0.001 1.002 (1.000–1.004) 0.032
Vitamin D baseline (ng/ml) 15.8 (3–76.2) 17.6 (3.1–84.3) 0.09
Vitamin D TW 24 (ng/ml) 16.7 (3.7–56.9) 16.35 (3.2–61.9) 0.5
IP10 baseline (pg/ml) 228 (58.4–2000) 279 (41.2–2000) 0.009 1.000 (0.999–1.001) 0.2
TSH (mIU/ml) 1.37 (0.02–12) 1.24 (0.01–5.03) 0.2
IL28B-rs12979860 (CC/non_CC) 85 [23,1%]/32 [8,79%] 118 [32,1%]/132 [35,9%] ,0.001 2.476 (1.289–4.757) 0.006
CYP27B1-rs10877012
(AA/non_AA)
27 [7,3%]/176 [48,0%] 12 [3,29%]/151 [41,2%] 0.06
CYP2R1- rs10741657
(AA/non_AA)
33 [9,0%]/170 [46,4%] 18 [4,9%]/145 [39,6%] 0.1
DHCR7-rs12785878
(TT/non_TT)
100 [26,6%]/109 [29%] 98 [26,1%]/68 [18,1%] 0.031 0.745 (0.417–1.331) 0.3
CYP24A1-rs6013897
(TT/non_TT)
128 [34,1%]/81 [21,6%] 104 [27,7%]/62 [16,5%] 0.7
DHCR7-rs7944926
(GG/non_GG)
106 [28,2%]/103 [27,4%] 98 [26,1%]/68 [18,1%] 0.1
DBP-rs2282679
(TT/non_TT)
111 [29,6%]/98 [26,1] 85 [22,6%]/81 [21,6%] 0.7
DBP-rs4588
(CC/non_CC)
107 [28,5%]/102 [27,2%] 81 [21,6%]/85 [22,6%] 0.6
DBP-rs7041
(GG/non_GG)
65 [17,3%]/144 [38,4%] 50 [13,3%]/116 [30,9%] 0.8
Fibrosis stage (0–2/3–4) 184 [48,6%]/19 [5,0%] 137 [43,0%]/38 [10,0%] ,0.001 1.489 (0.562–3.946) 0.4
Only patients with complete data for the remaining covariates (277 out of 398) and with significant variations in the univariate analysis were included in multivariate
analyses. Missing data and abbreviations are illustrated in the legend of Table 1. A VitD deficiency (,20 ng/ml) was observed in 251 (64,1%) out of 391patients. A liver
fibrosis stage of 0–2 was observed in 321 (84,9%) out of 378 patients, while 57 (15%) out of 378 patients showed a liver fibrosis stage of 3–4.
doi:10.1371/journal.pone.0087974.t002
Vitamin D Levels and Chronic Hepatitis C Infection
PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e87974
enzymes. Since HCV infection has been suggested by previous
studies to co-associate with VitD-deficiency [22,31,32], we further
intended to examine additionally whether the eradication of HCV
had a reciprocal effect on VitD levels. Moreover, it remains
unclear so far whether the additional evaluation of VitD levels
during antiviral therapy plays a role in predicting SVR rates.
Thereby we evaluated VitD concentrations at TW24 and beside
significant variations within VitD concentrations neither associa-
tions to therapy outcome nor normalization of VitD levels in
patients with SVR were identified at TW24.
Our results reveal substantial fluctuations of 25(OH)D3 levels
during antiviral therapy, which are affected by the month of blood
collection, yet no association to treatment outcome was identifi-
able. While patients achieving a SVR feature a slight elevation of
VitD levels between baseline and TW24 (from 15,8 ng/ml to
16,7 ng/ml) with nonSVR-patients featuring a slight reduction
respectively (from 17,6 ng/ml to 16,3 ng/ml), no statistical
significance has been observed between both groups. Also the
analysis of an already identified SNP (rs10741657) [33] within the
CYP2R1 enzyme, with the latter being expressed in the liver and
therefore among others being responsible for the generation of
25(OH)D3, showed no significant association to treatment
outcome. In contrast, the also already proposed SNP within the
CYP27B1 enzyme (rs10877012), responsible for the generation of
the active 1,25(OH)2D3, showed a non-significant trend to SVR-
(Table 2) in univariate analysis. We assume, that we were unable
to confirm the observed significant association [22] due to the fact
that the amount of patients being homozygote for the AA-allele
was very limited (39 out of 366) in our patient cohort. Despite the
fact that according to a recent study a prediction of SVR was
possible depending on identification of the wild type allele of the
Table 3. SNP’s within VitD regulating enzymes in association with baseline VitD values and VitD variations (DVitd) upon antiviral
therapy.
Polymorphism VitD ,20 ng/ml VitD $20 ng/ml p-value DvitD ,0 ng/ml DvitD $0 ng/ml p-value
CYP27B1-rs10877012
(AA/nonAA)1
28/205 11/122 0.2 16/151 21/141 0.3
CYP2R1- rs10741657 (AA/nonAA)2 30/203 21/112 0.4 23/144 18/144 0.4
DHCR7-rs12785878 (TT vs nonTT)3 113/120 81/50 0.014 78/75 86/69 0.4
CYP24A1-rs6013897 (TT vs nonTT)4 138/95 84/47 0.3 9/144 5/150 0.2
DHCR7-rs7944926 (GG vs nonGG)5 114/119 86/45 0.002 81/72 88/67 0.4
DBP-rs2282679 (TT vs nonTT)6 119/114 68/61 0.7 81/72 76/79 0.4
DBP-rs4588 (CC vs nonCC)7 112/121 67/64 0.5 77/76 70/85 0.3
DBP-rs7041 (GG vs nonGG)8 68/165 43/89 0.4 48/105 46/109 0.7
1,2DVitd values were missing in 37 patients, 3–8DVitd values were missing in 66 patients.
doi:10.1371/journal.pone.0087974.t003
Figure 2. High cholesterol- and low gGT- levels associate with
achievement of SVR and ETR.
doi:10.1371/journal.pone.0087974.g002
Figure 3. Variations of IP10-levels in patients with and without
SVR at baseline, week 1 and 4 upon treatment initiation.
doi:10.1371/journal.pone.0087974.g003
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VitD binding protein (DBP-rs4588 and -rs7041) [12], no
significant associations have been identified within our patient
cohort. However, we identified a significant association between
SVR rates and the rs12785878 SNP within the 7-dehydrocholes-
terol reductase (DHCR7). DHCR7 converts 7-dehydrocholesterol to
cholesterol thus removing the substrate from the synthetic pathway
of VitD and finally regulating VitD levels [28], which is in
accordance with our current observations (Table 3). Furthermore,
two recent studies identified the rs12785878 SNP within DHCR7
to associate significantly with liver fibrosis progression in genotype
1 HCV infected patients [34] and with HCV-associated hepato-
carcinogenesis respectively [35]. Thus, we further examined
whether the rs12785878 SNP within DHCR7 associated with
fibrosis progression in our patient cohort as well. Thereby, we
observed a significant association of the TT-genotype to fibrosis
stage F3–F4 (P=0.013) (Figure 4), which is in accordance with
previous published results [34]. Since patients with low fibrosis
show higher responsiveness to antiviral therapy compared to
patients with advanced fibrosis or cirrhosis, the significant
association of the DHCR7 genetic polymorphism to SVR rates
observed in our study appears logically consistent and adds further
valuable information regarding the role of DHCR7 and VitD
metabolism in chronic HCV infection.
While clinical guidelines define VitD levels of $30 ng/ml as
normal [19], we observed an overall VitD deficiency within the
entire patient cohort which persisted even during antiviral therapy
(Table 1). The already mentioned previous studies suggesting VitD
values being predictive of treatment response included patients
with overall higher mean levels of 25(OH)D3 concentrations
[10,12,13]. Thus, our results imply that the predictive ability of
baseline 25(OH)D3 values observed in previous studies disappears
in deficient concentration ranges. A possible explanation of this
observed phenomenon is that the proposed synergistic effect of
1,25(OH)2D3 and IFNa on the IFN-gene-expression and HCV
replication [15] may be so substantially diminished at deficient
concentration ranges that the predictive potential of VitD
concentrations disappears. Furthermore, it is well known that
25(OH)D3 serum concentrations correlate poorly with serum and
tissue levels of the bioactive vitamin D metabolite calcitriol [18]. In
a sub-analysis including only patients with normal VitD-concen-
trations ($30 ng/ml) still no significant association was observed
between baseline VitD-levels and SVR rates (P=0.1). However,
this sub-analysis could be confounded by the small amount of
patients having normal VitD-levels at baseline (n = 48) within our
patient cohort. Moreover, as above mentioned, primary studies
observing a positive correlation of VitD levels to SVR rates were
conducted in countries with higher sun exposure and thus higher
baseline VitD levels [11–14]. However, further studies with HIV/
HCV-coinfected patients, which were conducted in countries with
high sun exposure as well, failed to show a positive correlation of
VitD levels and SVR rates [16,17], with a recent swiss cohort [15]
even showing a positive trend between lower VitD levels and
higher SVR rates, which is in line with our current findings. Since
all trials, both in the Mediterranean area as well as in Northern
Europe, showed similar SVR rates, we may conclude that
variations within VitD levels are unable to predict SVR rates
especially in regions with higher rates of VitD-deficiency as this is
the case for Northern Europe.
Regarding the role of IP10, previous studies showed a
significant decline during antiviral therapy which remains
consistent in responders after HCV eradication and resolves with
persistence of chronic HCV infection in non-responders [36,37].
We observed a slight increase of IP10 levels at week 1 and a
consecutive decrease of IP10-levels at week 4, with IP10 levels
remaining predicting of SVR at each time point assessed, thus
underlying the importance of IP10 in predicting treatment
outcome. Therefore, we propose that especially the comprehensive
evaluation of IP10 levels during antiviral therapy, as for instance at
week 4, may increase the predictive potential of viral kinetics
assessed at this time point of antiviral therapy. Moreover, low
baseline gGT- and elevated cholesterol-levels appear as the
strongest predictors of SVR after the IL28B-CC-genotype in our
analysis. Since both parameters are routinely assessed in clinical
biochemical screenings the specific consideration of both factors in
clinical decisions might offer valuable comprehensive information
regarding treatment prediction according to our analysis. A
subanalysis within our patient cohort including patients with
IL28B-CC-genotype, low IP10-levels (,600ng/ml) [29], high
cholesterol-levels (cut-off value of 174 mg/ml, calculated by ROC-
analysis) and non-elevated gGT-values (n = 41), showed an SVR-
rate of 78,1% for these patients, which is similar to SVR-rates
achieved by the currently standard-of-care triple therapy in
genotype 1 patients with PEG-IFN/RBV in combination with
telaprevir or boceprevir, both direct ketoamide inhibitors of the
HCV-NS3-protease. Thus, we may conclude, that the PEG-IFN/
RBV combination therapy could still display an option for
carefully preselected patients according to the above mentioned
treatment predictors especially in areas with limited health care
budget.
Although offering promising results, our study had some
limitations. Beside the fact that it is retrospective, VitD concen-
trations and SNP’s were available only in a subgroup of the entire
patient cohort with possible selection bias not being excludable.
With an overall VitD-insufficiency observed in the patient cohort,
our study provides information regarding responsiveness to
antiviral treatment in VitD-insufficient genotype 1 HCV patients.
Despite our effort to minimize confounding factors such as
consideration of seasonal and on-treatment variability (Figure 1),
data on prevalence of osteoporosis and parathyroid dysfunction
were lacking in our analysis, thus potentially affecting the results of
our studies. Furthermore, our study was conducted prior to the
approval of direct acting NS3 protease inhibitors and therefore it
does not resemble the current standard of care for genotype 1
HCV infected patients. However, in many countries worldwide no
direct antiviral agents are yet available with PEG-IFN/RBV being
still the standard of care.
Figure 4. The DHCR7-TT-genotype of the rs12785878 SNP shows
a significant association to stage of fibrosis.
doi:10.1371/journal.pone.0087974.g004
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In conclusion, our study implies that VitD concentrations are
not a reliable prediction parameter in genotype 1 HCV patients
undergoing PEG-IFN/RBV antiviral therapy. Fluctuations in
VitD levels during antiviral therapy may be due to environmental
factors rather than to virus- or antiviral therapy-related effects
whereas the evaluation of SNP’s within VitD regulating enzymes
constitutes an important component in further deciphering the
role of VitD metabolism in chronic HCV infection.
Conclusions
N Vitamin D levels assessed at baseline and at therapy week 24
show substantial variations during antiviral therapy but are
unable to predict treatment outcome.
N The rs12785878 SNP within DHCR7 is significantly associated
with sustained viral response rates, whereas further SNP’s
within the Vitamin D binding protein and Vitamin D
regulating enzymes showed no significant associations.
N Baseline and under therapy IP10-levels are independently
predicting therapy outcome especially in IL28B-nonCC-
patients while low baseline gGT- and elevated cholesterol-
levels appear as the strongest predictors of therapy outcome
after the IL28B-CC-genotype.
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